RxDoctor Payments Data

James Burke

Neurology · Durham, NCNPI 1528141769

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $20,025 of the $21,264 with a category attached, or 94.2%. 4 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 56.4% of the total. Reporting peaked in 2019 at $19,203 and has fallen 98.6% since, to $260 in 2022.

$21,264in general payments, 2019–2025

Across 15 payments — averaging $1417.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$12K
  • Eisai Inc.$9K
  • Penumbra, Inc.$141
  • Intuitive Surgical$119
$1,524,132in research payments, 2019–2025

Across 45 payments — averaging $33,870 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$1.2M
  • AbbVie$292K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Merck$54

What the payments were for

  • Consulting fees$20,02594%
  • Travel & lodging$8154%
  • Food & beverage$4232%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,264 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →